Tianshu Pharmaceutical Assists CDMO Partner in Securing Official Acceptance of Class 1 New Drug Clinical Trial Application

Recently, the clinical trial application for a Class 1 new drug (capsule) developed by Tianshu Pharmaceutical's CDMO partner with its assistance was officially accepted by CDE.

　　It took only 9 months from the signing of the contract to the completion of the IND acceptance for this project. As an innovative drug CDMO, high-end API and advanced pharmaceutical intermediate supplier, and comprehensive solution provider, Tianshu Pharmaceutical, relying on the strong R&D strength of its headquarters, Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare), gave full play to its own industrialization advantages, providing services such as process development, toxicology sample supply, 30kg-scale GMP production and release for the project, helping the customer's Class 1 new drug clinical trial application to be officially accepted.

　　Tianshu Pharmaceutical will be committed to continuously providing efficient, convenient and high-quality CDMO services for customers, continuously optimizing project costs, stabilizing production cycles, ensuring product quality, and helping new drugs enter the market as soon as possible to benefit patients.